Isoflurane, like sepsis, decreases CYP1A2 liver enzyme activity in intensive care patients: a clinical study and network model.
Thomas KöhlerElke SchwierJanina PraxenthalerCarmen KirchnerGuenther WindeBjörn KoosDietrich HenzlerPublished in: Intensive care medicine experimental (2024)
Sepsis and isoflurane have independently demonstrated an effect on reducing the hepatic CYP1A2-activity. A network model was constructed that could explain the mechanism through the influence of isoflurane on hypoxia inducible factor (HIF-1α) by upregulation of the hypoxia-inducible pathway and the downregulation of CYP1A2-activity via the ligand-inducible pathway. Thus, the increased anaerobic metabolism may result in lactate accumulation. The influence of isoflurane sedation on the validated correlation of global liver function with CYP1A2-activity measured by LiMAx testing needs to be investigated in more detail.
Keyphrases
- end stage renal disease
- intensive care unit
- acute kidney injury
- wastewater treatment
- signaling pathway
- newly diagnosed
- chronic kidney disease
- ejection fraction
- endothelial cells
- microbial community
- prognostic factors
- mechanical ventilation
- peritoneal dialysis
- mass spectrometry
- risk assessment
- high resolution
- double blind